Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

Toward Individualized Pharmaceutical Care of East Asians

Research into the relationship between genetics and drug response has focused on polymorphisms, or variations, in genes that encode drug-metabolizing enzymes, particularly the genes that affect the clearance of the anticoagulant warfarin, proton pump inhibitors, tricyclic antidepressants, and many other clinically relevant drugs. Much of this work has targeted East Asians, a genetically distinguishable and populous group. Researchers have identified polymorphisms that inactivate gene function, compared polymorphism frequencies in East-Asian and Caucasian populations, and determined the effects on the pharmacokinetic parameters of drugs. Detection in an individual of polymorphisms known to inactivate a drug-metabolizing enzyme is predictive of poor metabolism of drugs processed by that pathway, which itself may be predictive of an atypical drug response. Genetic tests can be used to screen for individuals who are poor metabolizers, with the ultimate goal of better predicting the clinical effects of drugs.

Blog Post

#TBT: Why Patient Differences Matter, Especially When It Comes to Cancer Treatments

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

#TBT: Senior Citizens Day & Individualized Pharmaceutical Care

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

WASHINGTON, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

Michael Ciarametaro Joins National Pharmaceutical Council as Director of Research

WASHINGTON, DC (July 31, 2014)—The National Pharmaceutical Council (NPC) today announced that Michael Ciarametaro has joined the health policy...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards

Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

The Risks of Standardized Health Care

Think about the last time you visited a medical office. Even at a specialist’s office, chances are that each person waiting for his or her name to be...
Commentary and Testimony Page

Questions Abound on the Adoption of Evidence

Medical decision making should rely on evidence (when available) to ensure that treatments are appropriate and effective for patients. Given the...
Commentary and Testimony Page

Health Affairs CER Briefing Highlights Key Issues

Just one week after the appointment of the board of governors for the new comparative effectiveness research (CER) body, the Patient-Centered...
YouTube Videos

Using Distributed Data Networks to Understand Heterogeneity in Real-World Data

Kimberly Westrich, director of health services research at the National Pharmaceutical Council, explains how large observational datasets like...
YouTube Videos

Understanding Individual Patients' Health Care Needs

Paul Martino, SVP of Clinical Strategy and Innovation at WellPoint, Inc., explains that it's important for payers and other health care stakeholders...
YouTube Videos

Taking Patient Variations Into Account

Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...
YouTube Videos

Payer Views of Individualized Health Care

Dr. Daniel Malone, professor at the University of Arizona School of Pharmacy, explains how payers view the issue of individualized therapy. He says...
Blog Post

#TBT: Why Patient Differences Matter, Especially When It Comes to Cancer Treatments

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

#TBT: Senior Citizens Day & Individualized Pharmaceutical Care

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

#TBT: Ethnic Disparities in the Burden and Treatment of Asthma

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

NPC to Discuss Role of Pharmaceuticals, Applying Real-World Evidence at ISPOR Annual Meeting

Planning to attend the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 19th Annual International Meeting in Montreal May...

Research

JCER

The Emerging Relevance of Heterogeneity of Treatment Effect in Clinical Care: A Study Using Stage IV Prostate Cancer as a Model

Although researchers and health care providers widely recognize that individuals with stage IV...
  •  
  • 1 of 29
  • >

Commentary & Testimony